by NanoVation | Oct 18, 2022 | 2022, News, News & Events
News Innovate BC supports NanoVation project to improve mRNA stability and production for vaccines L to R: Don Enns (NTx), Jayesh Kulkarni (NTx), Nadine Diner (Innovate BC), Eric Jan (UBC), Yihang Chen (UBC), Kate Hollinshead (NTx) A project being led by NanoVation...
by NanoVation | Oct 11, 2022 | 2022, News, News & Events
News Co-Founder Dr. Pieter Cullis wins 2022 Bloom Burton Award The Board Chair and Co-Founder of NanoVation Therapeutics, Dr. Pieter Cullis, has received another honour in recognition of his pioneering work on the development of lipid nanoparticle (LNP) delivery...
by NanoVation | Sep 14, 2022 | 2022, News, News & Events
News NanoVation Therapeutics™ & Baseimmune announce innovative mRNA vaccine collaboration Dr. Joshua Blight, Co-Founder & CEO of Baseimmune Companies to collaborate on designing ‘universal antigens’ for broad-spectrum mRNA vaccines against COVID, malaria and...
by NanoVation | Sep 1, 2022 | 2022, 2022, News, News & Events, Publications
Publication NTx scientists publish in European J. of Pharm. Sciences Lipid nanoparticle formulations for optimal RNA-based topical delivery to murine airways Tam et al. 1 September 2022 Co-authored by NTx scientists Drs. Anthony Tam, Jayesh A Kulkarni, Kevin An,...
by NanoVation | Jun 27, 2022 | 2022, 2022, News, News & Events, Publications
Publication NTx’s Dr. Arpan Desai publishes in Journal of Controlled Release Lipid-peptide nanocomplexes for mRNA delivery in vitro and in vivo Grant-Serroukh et al. 26 June 2022 Co-authored by NanoVation’s Dr. Arpan Desai (UK). Abstract Despite recent advances...
by NanoVation | Jun 17, 2022 | 2022, 2022, News, News & Events, Publications
Publication NTx’s Drs. Jayesh Kulkarni & Pieter Cullis publish in Langmuir Synthesis and Characterization of Hybrid Lipid Nanoparticles Containing Gold Nanoparticles and a Weak Base Drug Zhigaltsev et al. 16 June 2022 Co-authored by NanoVation’s Drs Jayesh...
